{"symbol":"BMY","fiscalQuarter":"Q1-2025","reportDate":"2025-04-24","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q1-2025","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 0.33%","keyNumbers":[{"metric":"EPS","actual":"$1.80","expected":"N/A","surprise":"+19.52%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in key therapeutic areas.","They expressed confidence in the ongoing pipeline developments."],"summary":"Overall, management conveyed a positive outlook on the company's performance despite not providing specific guidance. They emphasized the strength of their product portfolio."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance indicates better-than-expected profitability, which contributed to a slight increase in stock price. However, the lack of revenue data and guidance may leave investors cautious. The stock's modest rise reflects investor sentiment following the earnings surprise.","metaDescription":"Bristol Myers Squibb (BMY) Q1 2025 earnings: EPS beat by 19.52%. Stock up 0.33%. Full breakdown."}}